Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on August 5, 2013. The report discloses the entry into a Material Definitive Agreement with Mallinckrodt LLC regarding the supply of sufentanil for the Company's Zalviso (Sufentanil NanoTab PCA System).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of a new supply agreement.
Material Changes and Agreement Terms
- Agreement Type: Supply Agreement effective as of May 31, 2013.
- Counterparty: Mallinckrodt LLC.
- Product: Sufentanil for use with the Zalviso system.
- Commitment: AcelRx agreed to purchase at least 80% of its product requirements from Mallinckrodt during the term.
- Forecasting: AcelRx must provide a rolling 12-month forecast of requirements on a quarterly basis, starting January 1, 2013.
- Term: The agreement extends until December 31, 2016, extendable only by written mutual agreement.
- Pricing: Establishes pricing for bulk product, subject to annual adjustment.
Outlook, Risks, and Contingencies
The agreement includes specific termination rights and contingencies:
- Supply Failure Contingency: If Mallinckrodt fails to supply required quantities meeting specifications within 15 days of the delivery date on two or more occasions during any Contract Year, AcelRx is relieved of the 80% purchase obligation and may purchase unlimited quantities from other suppliers.
- Breach Termination: Either party may terminate the agreement if the other materially breaches and fails to cure the breach within 30 days of written notice.
- Documentation: The full text of the Supply Agreement is scheduled to be filed as an exhibit to the Company's Form 10-Q for the quarter ending September 30, 2013.
Investor Verification Checklist
- Verify the specific pricing terms and annual adjustment mechanisms in the full Supply Agreement exhibit.
- Monitor future 10-Q filings for the rolling forecasts provided to Mallinckrodt.
- Assess the impact of the 80% supply commitment on the Company's operational flexibility and cost structure.
- Review the Company's historical supply chain reliability to evaluate the risk of triggering the "two or more occasions" termination clause.